β-endorphin peptides for treating muscle-wasting diseases
AssigneeThe University of Birmingham
InventorMargaret E Smith
Life of this patent
Estimating the term…
Abstract
An active β-endorphin fragment or an analog of such a fragment is provided to a patient for alleviating the effect of muscle-wasting disease and for inhibiting or reducing leakage of an enzyme from a living muscle. The β-endorphin fragment is selected from β-endorphin (30, 31), β-endorphin (29-31), β-endorphin (28-31) and stabilized analogs thereof.
Claims10
A method of treating a patient for alleviating the effect of muscle-wasting disease, or for inhibiting or reducing leakage of an enzyme from a living muscle, comprising the step of administering to such patient an active C-terminal β-endorphin fragment or an active analogue of such a fragment wherein said fragment or analogue thereof inhibits leakage of creatine phosphokinase from living muscle.
A method of treating a patient for alleviating the effect of muscle-wasting disease, or for inhibiting or reducing leakage of an enzyme from a living muscle, comprising the step of administering to such patient an active C-terminal β-endorphin fragment or an active analogue of such a fragment, wherein said fragment or analogue thereof inhibits leakage of creatine phosphokinase from living muscle and said active analogue has one or more of the following substitutions relative to a reference human β-endorphin SEQ ID No. 1:
- Amino Acid Substituting Moiety 28 Orn, MeLys, des-NH2, Nle or D-Lys 29 Orn, D-Lys, MeLys or Nle 30 Sar, AzGly, Ala, D-Ala, D-Ser or Pro 31 Gln;
- with the proviso that the analogue cannot be Gly-Gln or Ac-Lys-D-Lys-Sar-Glu-OH.
Dependencies are inferred from the claim text.